10X Change To Inventory vs Free Cash Flow Analysis

TXG Stock

USD 16.15 0.28 1.76%

10X Genomics financial indicator trend analysis is way more than just evaluating 10X Genomics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether 10X Genomics is a good investment. Please check the relationship between 10X Genomics Change To Inventory and its Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

Change To Inventory vs Free Cash Flow

Change To Inventory vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of 10X Genomics Change To Inventory account and Free Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between 10X Genomics' Change To Inventory and Free Cash Flow is 0.59. Overlapping area represents the amount of variation of Change To Inventory that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of 10X Genomics, assuming nothing else is changed. The correlation between historical values of 10X Genomics' Change To Inventory and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Change To Inventory of 10X Genomics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Change To Inventory i.e., 10X Genomics' Change To Inventory and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

0.59

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Change To Inventory

The increase or decrease in the amount of inventory a company has over a certain period.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from 10X Genomics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into 10X Genomics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.At this time, 10X Genomics' Issuance Of Capital Stock is most likely to decrease significantly in the upcoming years. The 10X Genomics' current Sales General And Administrative To Revenue is estimated to increase to 0.64, while Tax Provision is projected to decrease to roughly 3.7 M.

	2021	2022	2023	2024 (projected)
Interest Expense	866K	476K	33K	31.4K
Depreciation And Amortization	28.3M	33.0M	43.6M	45.8M

Interest Expense Depreciation And Amortization

10X Genomics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets
Total Assets		0.96	0.98	0.99	1.0	0.2	0.97	0.9	0.75	-0.81	-0.91	0.81	0.87	0.94	0.29	0.5	0.78	0.95	0.92	0.97	1.0	0.78	-0.74	0.95	0.91	0.88
Short Long Term Debt Total	0.96		0.94	0.98	0.94	0.05	0.93	0.97	0.81	-0.65	-0.95	0.86	0.74	0.98	0.1	0.3	0.79	0.84	0.99	0.91	0.95	0.79	-0.61	0.95	0.98	0.8
Other Current Liab	0.98	0.94		0.99	0.98	0.11	0.95	0.87	0.71	-0.82	-0.91	0.72	0.88	0.9	0.2	0.56	0.76	0.95	0.89	0.93	0.97	0.76	-0.73	0.94	0.88	0.94
Total Current Liabilities	0.99	0.98	0.99		0.98	0.11	0.96	0.93	0.78	-0.75	-0.94	0.79	0.83	0.95	0.19	0.47	0.78	0.92	0.94	0.95	0.98	0.78	-0.71	0.96	0.93	0.88
Total Stockholder Equity	1.0	0.94	0.98	0.98		0.18	0.97	0.89	0.72	-0.82	-0.89	0.79	0.88	0.93	0.3	0.52	0.71	0.95	0.9	0.97	0.99	0.71	-0.8	0.94	0.9	0.88
Other Liab	0.2	0.05	0.11	0.11	0.18		0.12	-0.05	-0.04	-0.39	0.04	0.25	0.35	0.07	0.95	0.55	0.5	0.31	0.03	0.34	0.23	0.5	0.08	0.05	-0.03	0.05
Net Tangible Assets	0.97	0.93	0.95	0.96	0.97	0.12		0.88	0.85	-0.78	-0.96	0.77	0.85	0.92	0.23	0.45	0.71	0.92	0.9	0.96	0.97	0.71	-0.78	0.99	0.89	0.85
Property Plant And Equipment Net	0.9	0.97	0.87	0.93	0.89	-0.05	0.88		0.82	-0.49	-0.92	0.88	0.59	0.99	0.03	0.14	0.67	0.73	0.99	0.85	0.9	0.67	-0.64	0.91	1.0	0.67
Current Deferred Revenue	0.75	0.81	0.71	0.78	0.72	-0.04	0.85	0.82		-0.42	-0.94	0.7	0.52	0.82	-0.01	0.09	0.64	0.6	0.84	0.76	0.76	0.64	-0.51	0.9	0.8	0.54
Net Debt	-0.81	-0.65	-0.82	-0.75	-0.82	-0.39	-0.78	-0.49	-0.42		0.62	-0.41	-0.99	-0.57	-0.49	-0.8	-0.64	-0.94	-0.56	-0.82	-0.81	-0.64	0.67	-0.71	-0.52	-0.9
Retained Earnings	-0.91	-0.95	-0.91	-0.94	-0.89	0.04	-0.96	-0.92	-0.94	0.62		-0.77	-0.71	-0.93	-0.01	-0.26	-0.73	-0.8	-0.94	-0.88	-0.91	-0.73	0.64	-0.99	-0.92	-0.78
Accounts Payable	0.81	0.86	0.72	0.79	0.79	0.25	0.77	0.88	0.7	-0.41	-0.77		0.51	0.91	0.28	0.05	0.71	0.65	0.89	0.78	0.82	0.71	-0.45	0.78	0.9	0.46
Cash	0.87	0.74	0.88	0.83	0.88	0.35	0.85	0.59	0.52	-0.99	-0.71	0.51		0.67	0.44	0.76	0.7	0.97	0.65	0.88	0.87	0.7	-0.7	0.79	0.62	0.92
Non Current Assets Total	0.94	0.98	0.9	0.95	0.93	0.07	0.92	0.99	0.82	-0.57	-0.93	0.91	0.67		0.16	0.23	0.72	0.79	0.99	0.91	0.95	0.72	-0.67	0.93	0.99	0.7
Non Currrent Assets Other	0.29	0.1	0.2	0.19	0.3	0.95	0.23	0.03	-0.01	-0.49	-0.01	0.28	0.44	0.16		0.62	0.39	0.41	0.08	0.44	0.33	0.39	-0.19	0.13	0.04	0.13
Other Assets	0.5	0.3	0.56	0.47	0.52	0.55	0.45	0.14	0.09	-0.8	-0.26	0.05	0.76	0.23	0.62		0.48	0.7	0.19	0.56	0.51	0.48	-0.43	0.36	0.15	0.68
Long Term Debt	0.78	0.79	0.76	0.78	0.71	0.5	0.71	0.67	0.64	-0.64	-0.73	0.71	0.7	0.72	0.39	0.48		0.74	0.76	0.78	0.77	1.0	-0.18	0.73	0.69	0.65
Cash And Short Term Investments	0.95	0.84	0.95	0.92	0.95	0.31	0.92	0.73	0.6	-0.94	-0.8	0.65	0.97	0.79	0.41	0.7	0.74		0.77	0.93	0.94	0.74	-0.74	0.87	0.75	0.94
Net Receivables	0.92	0.99	0.89	0.94	0.9	0.03	0.9	0.99	0.84	-0.56	-0.94	0.89	0.65	0.99	0.08	0.19	0.76	0.77		0.89	0.93	0.76	-0.59	0.93	0.99	0.7
Common Stock Total Equity	0.97	0.91	0.93	0.95	0.97	0.34	0.96	0.85	0.76	-0.82	-0.88	0.78	0.88	0.91	0.44	0.56	0.78	0.93	0.89		0.99	0.78	-0.74	0.92	0.86	0.81
Common Stock Shares Outstanding	1.0	0.95	0.97	0.98	0.99	0.23	0.97	0.9	0.76	-0.81	-0.91	0.82	0.87	0.95	0.33	0.51	0.77	0.94	0.93	0.99		0.77	-0.75	0.95	0.91	0.85
Long Term Debt Total	0.78	0.79	0.76	0.78	0.71	0.5	0.71	0.67	0.64	-0.64	-0.73	0.71	0.7	0.72	0.39	0.48	1.0	0.74	0.76	0.78	0.77		-0.18	0.73	0.69	0.65
Non Current Liabilities Total	-0.74	-0.61	-0.73	-0.71	-0.8	0.08	-0.78	-0.64	-0.51	0.67	0.64	-0.45	-0.7	-0.67	-0.19	-0.43	-0.18	-0.74	-0.59	-0.74	-0.75	-0.18		-0.72	-0.63	-0.7
Capital Surpluse	0.95	0.95	0.94	0.96	0.94	0.05	0.99	0.91	0.9	-0.71	-0.99	0.78	0.79	0.93	0.13	0.36	0.73	0.87	0.93	0.92	0.95	0.73	-0.72		0.91	0.82
Inventory	0.91	0.98	0.88	0.93	0.9	-0.03	0.89	1.0	0.8	-0.52	-0.92	0.9	0.62	0.99	0.04	0.15	0.69	0.75	0.99	0.86	0.91	0.69	-0.63	0.91		0.69
Other Current Assets	0.88	0.8	0.94	0.88	0.88	0.05	0.85	0.67	0.54	-0.9	-0.78	0.46	0.92	0.7	0.13	0.68	0.65	0.94	0.7	0.81	0.85	0.65	-0.7	0.82	0.69

Click cells to compare fundamentals

10X Genomics Account Relationship Matchups

10X Genomics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	605.9M	929.3M	1.0B	1.0B	965.1M	746.1M
Short Long Term Debt Total	29.7M	63.0M	82.0M	95.2M	95.4M	63.7M
Other Current Liab	36.8M	88.4M	72.8M	79.3M	70.2M	58.9M
Total Current Liabilities	63.0M	118.1M	110.4M	131.0M	127.2M	94.9M
Total Stockholder Equity	420.1M	739.1M	817.6M	805.7M	741.0M	501.4M
Other Liab	103.0M	15.1M	14.1M	6.1M	5.5M	5.3M
Net Tangible Assets	397.7M	739.1M	787.7M	778.4M	895.1M	939.9M
Property Plant And Equipment Net	48.8M	119.8M	230.4M	359.2M	344.9M	176.2M
Current Deferred Revenue	3.3M	4.5M	5.3M	7.9M	13.2M	13.8M
Net Debt	(394.4M)	(600.6M)	(505.5M)	(124.6M)	(263.9M)	(277.1M)
Retained Earnings	(262.4M)	(805.1M)	(863.3M)	(1.0B)	(1.3B)	(1.2B)
Accounts Payable	13.0M	4.7M	17.4M	21.6M	15.7M	13.6M
Cash	424.2M	663.6M	587.4M	219.7M	359.3M	372.0M
Non Current Assets Total	125.1M	155.0M	271.2M	393.9M	369.1M	210.6M
Non Currrent Assets Other	76.3M	12.8M	10.9M	7.4M	3.1M	2.9M
Other Assets	53.9M	82.1M	10.9M	7.4M	8.5M	8.0M
Cash And Short Term Investments	424.2M	663.6M	587.4M	430.0M	388.7M	409.6M
Net Receivables	33.4M	51.2M	85.3M	104.2M	114.8M	67.9M
Common Stock Shares Outstanding	78.2M	101.2M	110.3M	113.9M	117.2M	85.8M
Liabilities And Stockholders Equity	605.9M	929.3M	1.0B	1.0B	965.1M	746.1M
Non Current Liabilities Total	122.8M	72.1M	90.9M	92.3M	96.9M	108.9M
Capital Surpluse	682.5M	1.5B	1.7B	1.8B	2.1B	2.2B
Inventory	15.3M	30.0M	60.0M	81.6M	73.7M	43.0M
Other Current Assets	8.0M	42.6M	28.8M	19.2M	18.8M	19.3M
Other Stockholder Equity	76.6M	1.5B	1.7B	1.8B	2.0B	1.1B
Total Liab	185.8M	190.3M	201.3M	223.2M	224.1M	178.0M
Net Invested Capital	449.8M	739.1M	817.6M	805.7M	741.0M	512.4M
Property Plant And Equipment Gross	48.8M	72.8M	230.4M	359.2M	448.4M	470.8M
Total Current Assets	480.8M	774.4M	747.6M	635.0M	596.0M	535.6M
Accumulated Other Comprehensive Income	(46K)	(50K)	22K	(4.3M)	(429K)	(450.5K)
Non Current Liabilities Other	1.1M	72.1M	90.9M	6.1M	4.3M	4.1M
Net Working Capital	417.8M	656.2M	637.2M	504.1M	468.9M	440.6M
Short Term Debt	9.9M	11.9M	10.3M	18.1M	23.0M	12.8M
Property Plant Equipment	48.8M	72.8M	230.4M	289.3M	332.7M	349.4M

Currently Active Assets on Macroaxis

C	Citigroup
GM	General Motors
F	Ford Motor
GM	General Motors
V	Visa Class A

When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:

How To Invest In 10X

Details

Is 10X Stock a good investment?

Details

What is 10X Genomics' Net Worth?

Details

Largest Life Sciences Tools & Services Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.

You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.52)

Revenue Per Share

5.261

Quarterly Revenue Growth

(0.01)

Return On Assets

(0.11)

Return On Equity

(0.25)

The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between 10X Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

10X Change To Inventory vs Free Cash Flow Analysis

Change To Inventory vs Free Cash Flow

Change To Inventory vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Change To Inventory

Free Cash Flow

10X Genomics fundamental ratios Correlations

10X Genomics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

10X Genomics fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Common Stock Shares Outstanding	+ 1.0	Total Assets
Inventory	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Liabilities	+ 0.99	Total Assets
Net Receivables	+ 0.99	Short Long Term Debt Total

Capital Surpluse	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Retained Earnings	- 0.96	Net Tangible Assets
Retained Earnings	- 0.95	Short Long Term Debt Total
Net Receivables	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.94	Net Debt